Purpose of review Summarizing the current preclinical and clinical evidence about bystander effect of antibody-drug conjugates (ADCs) in solid tumors. Recent findings One of the main challenges of treating solid tumors with ADCs is the heterogeneous expression of the target antigen (Ag), which however may be overcome by the so-called bystander killing effect. This unique, but still debated, feature of certain ADCs is represented by the unintentional payload diffusion from Ag-positive tumor cells to adjacent Ag-negative tumor cells. Some pharmacological characteristics, such as a hydrophobic payload or a cleavable linker, seem to play a major role in this effect. Abundant preclinical evidence of the bystander effect has emerged, and the clinical activity of ADCs in tumors with a heterogeneous Ag expression suggests the relevance of this feature. Additional studies are required to investigate if the bystander effect is necessary for achieving a solid activity with ADCs.

Bystander effect of antibody-drug conjugates: fact or fiction? / F. Giugliano, C. Corti, P. Tarantino, F. Michelini, G. Curigliano. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - 24:7(2022 Jul), pp. 809-817. [10.1007/s11912-022-01266-4]

Bystander effect of antibody-drug conjugates: fact or fiction?

F. Giugliano
Primo
;
C. Corti
Secondo
;
P. Tarantino
;
F. Michelini
Penultimo
;
G. Curigliano
Ultimo
2022

Abstract

Purpose of review Summarizing the current preclinical and clinical evidence about bystander effect of antibody-drug conjugates (ADCs) in solid tumors. Recent findings One of the main challenges of treating solid tumors with ADCs is the heterogeneous expression of the target antigen (Ag), which however may be overcome by the so-called bystander killing effect. This unique, but still debated, feature of certain ADCs is represented by the unintentional payload diffusion from Ag-positive tumor cells to adjacent Ag-negative tumor cells. Some pharmacological characteristics, such as a hydrophobic payload or a cleavable linker, seem to play a major role in this effect. Abundant preclinical evidence of the bystander effect has emerged, and the clinical activity of ADCs in tumors with a heterogeneous Ag expression suggests the relevance of this feature. Additional studies are required to investigate if the bystander effect is necessary for achieving a solid activity with ADCs.
Antibody–drug conjugates; Bystander effect; Sacituzumab govitecan; Trastuzumab deruxtecan; Trastuzumab emtansine
Settore MED/06 - Oncologia Medica
lug-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
bbb-s11912-022-01266-4 (1).pdf

accesso riservato

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 2.22 MB
Formato Adobe PDF
2.22 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/985552
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 33
social impact